Pivotal Phase 3 ARTEMIS Trial Data Demonstrates Consistent Safety and Efficacy of AR101 in Children and Adolescents with Peanut Allergy
LISBON, Portugal--(BUSINESS WIRE)--Jun 2, 2019--
LISBON, Portugal--(BUSINESS WIRE)--Jun 2, 2019--